Blackburn, MBBS
Vice President, Global Head of Risk Management, Real-World & Late Phase Research

Dr. Stella Blackburn leads risk management efforts in North America, Europe and Asia-Pacific for the Quintiles real-world and late phase research group. In her role, Dr. Blackburn develops multidisciplinary benefit risk management services, reviews and assists customers with interpretation of pharmacovigilance legislation, and ensures compliance with regulations and best practices in the conduct of pharmacovigilance and risk management activities for the company’s real-world and late phase research efforts.

With more than two decades of experience in the pharmacovigilance and pharmacoepidemiology fields, Dr. Blackburn joined Quintiles from the European Medicines Agency (EMA) where she served for more than 16 years in various roles, most recently as the EMA Risk Management Development and Scientific Lead. In this role, Dr. Blackburn was responsible for designing and implementing risk management public policy and processes used throughout Europe. Dr. Blackburn also worked with biopharmaceutical companies, government bodies and industry consortia to advance risk management and real-world research, including registry projects and public-private partnerships.

Before joining the EMA, Dr. Blackburn worked in hospital medicine and also spent more than 11 years in the pharmaceutical industry in a variety of leadership roles. Throughout her career, Dr. Blackburn has lectured around the world on pharmacovigilance and risk management and written chapters on the same topic in several textbooks and industry-related guides. Dr. Blackburn is also the past-President of the International Society of Pharmacoepidemiology. Dr. Blackburn trained in medicine at the University of Cambridge and the University of London Guy’s Hospital Medical School. She earned her Master of Science in Epidemiology from the London School of Hygiene and Tropical Medicine.

She is a Fellow of the Royal College of Physicians of Edinburgh, the International Society of Pharmacoepidemiology and the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians in the UK.


Media Inquiries

Make your own media inquiry